Hospital
Norman Regional Hospital Authority
Norman Regional Hospital Authority was paid $37.82M by Medicaid between Jan 2018 and Nov 2024, across 140 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoNORMAN REGIONAL HOSPITAL AUTHORITY
NORMAN, OK 73072
NORMAN, OK 73072
33aNPI1700882578assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.82M
24GClaims467,711
24DCodes billed140
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#4 of 75
Median peer was paid$3.66M
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,813 | $4.05M | |
| 2019 | 50,340 | $4.44M | |
| 2020 | 37,852 | $3.31M | |
| 2021 | 67,391 | $5.22M | |
| 2022 | 106,592 | $7.96M | |
| 2023 | 110,183 | $8.51M | |
| 2024incomplete | 43,540 | $4.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 43,171 | 42,741 | $10.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 62,124 | 61,836 | $10.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 28,478 | 28,337 | $9.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9.1% | 24,866 | 24,702 | $3.45M |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 54,183 | 52,271 | $497K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 6,536 | 6,419 | $472K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 8,897 | 8,704 | $387K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,042 | 4,028 | $369K |
| 80053 | Comprehensive metabolic panel | <1% | 33,670 | 33,323 | $320K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40,203 | 39,551 | $253K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,616 | 1,606 | $221K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 813 | 804 | $170K |
128 more codes
| A0427 | Emergency ambulance ride, advanced life support | <1% | 4,006 | $166K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,886 | $162K |
| 81001 | <1% | 36,331 | $143K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,121 | $126K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,030 | $96K |
| 87400 | <1% | 2,842 | $79K | |
| 87631 | <1% | 539 | $66K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 868 | $65K |
| 87428 | <1% | 2,301 | $65K | |
| 80050 | General health panel | <1% | 2,011 | $60K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,552 | $56K |
| 84703 | <1% | 7,544 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 689 | $40K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,421 | $40K |
| A0425 | Ground mileage, per statute mile | <1% | 7,248 | $37K |
| 80061 | Lipid panel | <1% | 3,041 | $35K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,743 | $33K |
| 88312 | <1% | 269 | $28K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,173 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 787 | $25K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 787 | $25K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 296 | $23K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 700 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,207 | $19K |
| 83690 | <1% | 3,327 | $19K | |
| 80074 | <1% | 411 | $17K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 319 | $17K |
| 36902 | <1% | 15 | $15K | |
| 88313 | <1% | 189 | $13K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 76 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,153 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 465 | $9K |
| 86160 | <1% | 459 | $8K | |
| 86885 | <1% | 1,650 | $8K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 37 | $8K |
| 83735 | <1% | 1,374 | $8K | |
| 86592 | <1% | 1,913 | $7K | |
| 86762 | <1% | 495 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 899 | $6K |
| 84484 | <1% | 469 | $6K | |
| 97597 | <1% | 572 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 150 | $5K |
| 87581 | <1% | 150 | $5K | |
| 87486 | <1% | 151 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 102 | $5K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 154 | $5K |
| 86140 | <1% | 1,184 | $5K | |
| 86803 | <1% | 402 | $5K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 99 | $5K |
| 84439 | <1% | 497 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 64 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 38 | $3K |
| 85652 | <1% | 1,512 | $3K | |
| 84112 | <1% | 41 | $3K | |
| 86900 | <1% | 913 | $2K | |
| 87081 | <1% | 394 | $2K | |
| 86901 | <1% | 899 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 213 | $2K |
| 86703 | <1% | 279 | $2K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 15 | $2K |
| 85730 | <1% | 463 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 147 | $2K |
| 86235 | <1% | 47 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 152 | $2K |
| 86812 | <1% | 91 | $2K | |
| 87340 | <1% | 192 | $2K | |
| 85027 | <1% | 319 | $2K | |
| 87070 | <1% | 243 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,580 | $2K |
| 85610 | <1% | 516 | $2K | |
| 93351 | <1% | 12 | $2K | |
| 82950 | <1% | 311 | $1K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 12 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 34 | $1K |
| 83655 | <1% | 110 | $1K | |
| 71250 | <1% | 26 | $1K | |
| 82728 | <1% | 79 | $999.13 | |
| 86200 | <1% | 83 | $876.17 | |
| 86704 | <1% | 76 | $793.28 | |
| 84702 | <1% | 64 | $735.10 | |
| 87210 | <1% | 165 | $717.44 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 95 | $679.53 |
| 87660 | <1% | 43 | $677.54 | |
| 87510 | <1% | 43 | $677.54 | |
| 87480 | <1% | 43 | $661.54 | |
| 73562 | <1% | 26 | $654.00 | |
| 86787 | <1% | 55 | $614.08 | |
| 86038 | <1% | 60 | $602.26 | |
| 86706 | <1% | 56 | $525.25 | |
| 86376 | <1% | 41 | $491.72 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $469.70 |
| 87280 | <1% | 31 | $370.14 | |
| 72100 | <1% | 17 | $343.51 | |
| 86225 | <1% | 29 | $342.16 | |
| 72202 | <1% | 15 | $329.98 | |
| 82731 | <1% | 12 | $327.00 | |
| 86431 | <1% | 74 | $322.56 | |
| 73130 | <1% | 14 | $302.64 | |
| 84550 | <1% | 83 | $297.48 | |
| 83540 | <1% | 53 | $247.25 | |
| 83550 | <1% | 41 | $240.87 | |
| 73620 | <1% | 14 | $227.89 | |
| 82550 | <1% | 41 | $220.02 | |
| 83021 | <1% | 13 | $208.78 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 118 | $204.24 |
| 80179 | <1% | 12 | $198.96 | |
| 80143 | <1% | 12 | $198.96 | |
| 84481 | <1% | 12 | $180.84 | |
| 83020 | <1% | 13 | $148.85 | |
| 82570 | <1% | 38 | $133.69 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15 | $125.96 |
| 85018 | <1% | 48 | $98.96 | |
| 85014 | <1% | 48 | $97.64 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,986 | $87.17 |
| 81002 | <1% | 27 | $74.36 | |
| 84156 | <1% | 28 | $61.94 | |
| 83615 | <1% | 13 | $59.07 | |
| 82043 | <1% | 12 | $48.54 | |
| J3490 | Unclassified drugs | <1% | 220 | $45.50 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,385 | $3.10 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15 | $2.89 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,357 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 175 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 37 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 330 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 64 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWAGNER, RICHARD (CO-CEO)
| Provider | Location | Paid |
|---|---|---|
| Norman Regional Hospital Emsstat | Norman, OK | $7.23M |
| Norman Regional Hospital Authority | Norman, OK | $5.50M |
| Norman Regional Providers Specialty Care | Norman, OK | $1.89M |
| Norman Regional Providers Primary Care | Norman, OK | $777K |
| NRHS Radiology Associates | Norman, OK | $630K |
| Wagner, Kuntz & Grabouski | Sioux City, IA | $597K |
| Norman Regional Hospital Authority | Norman, OK | $517K |
| Ventura Urgent Care Center Medical Corp | Ventura, CA | $53K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.